Antibody-Drug Conjugate
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
2024-01-09
Reviewing the Market Trends in the Antibody-Drug Conjugate Development: A Focus on Roche, Sanofi, BMS, Seagen, and BioNTech
2024-01-05
SystImmune Partners with Bristol-Myers Squibb to Develop and Commercialize Bispecific ADC Globally
2023-12-13
2023 ASCO Annual Meeting: Progress in Solid Tumor Treatment Research, and Promising Results in Emerging Therapies
2023-07-03
Following Amgen, Hummingbird Jumps Onto Synaffix’s ADC Platform In $150 Million Licensing Deal
2023-01-06